Developer docs
API playgroundTry for free, no card

Search company profiles

Altimmune

Full company profile

uuid0000b3l

Namestring
Altimmune
Legal namestring
Altimmune, Inc.
Websiteurl
altimmune.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide-based therapeutic with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity. The company is advancing pemvidutide across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). MASH is the lead indication, where pemvidutide has received both FDA Breakthrough Therapy Designation and Fast Track Designation, supported by positive Phase 2b IMPACT trial data demonstrating 7.5% weight loss, 23.7% triglyceride reduction, 15.4% total cholesterol reduction, and statistically significant MASH resolution without worsening of fibrosis at 24 weeks. AUD has received Fast Track Designation with Phase 2 RECLAIM topline data expected in Q3 2026, and the Phase 2 RESTORE trial in ALD was initiated in July 2025. The technology differentiates from GLP-1-only therapies through direct liver effects mediated by the glucagon receptor pathway.

Altimmune operates as a single-asset company — all three indications flow from the same pemvidutide molecule — and is currently pre-commercial, with Q4 2025 revenue of just $26,000. The company plans to initiate the Phase 3 PERFORMA trial in MASH in H2 2026 with an estimated program cost of approximately $400 million. The business model is pharmaceutical drug development and commercialization; upon approval, revenue is expected to be generated through specialty pharmacy and healthcare provider distribution channels, with analyst peak revenue estimates of $600 million to $1 billion from approximately 20,000 MASH patients.

The company is publicly traded on NASDAQ (ticker: ALT), headquartered in Gaithersburg, MD with a planned relocation to Morristown, NJ in late 2026. As of April 30, 2026, the company held approximately $535 million in cash following two equity offerings in early 2026 totaling approximately $300 million. The senior leadership team was substantially refreshed in 2025-2026 with appointments from Intercept Pharmaceuticals and Sanofi, including CEO Jerome Durso (former CEO/COO of Intercept), CCO Linda Richardson (former CCO of Intercept and Sanofi GLP-1 franchise leader), and CMO Christophe Arbet-Engels (former CMO at X4 Pharmaceuticals, Neurogastrx, and others). The company operates independently without parent or subsidiary structure, though it has secured up to $100 million in debt financing from Hercules Capital in addition to its equity raises.

Short descriptiontext

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a proprietary 1:1 glucagon/GLP-1 dual receptor agonist peptide, for the treatment of MASH, AUD, and ALD. The company is pre-commercial and preparing to initiate a Phase 3 trial in MASH.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGaithersburg, United States
HQ citystring
Gaithersburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics development, liver disease treatments, MASH drug development, metabolic disease therapeutics, GLP-1 glucagon agonists
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide for liver diseases. Once approved, the company plans to commercialize the drug for MASH, AUD, and ALD indications. Analysts estimate peak revenue potential of $600 million to $1 billion from approximately 20,000 patients.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, for the treatment of serious liver diseases. The lead candidate is being advanced across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 7.5% weight loss at 1.8 mg dose vs 0.2% for placebo in 48-week MASH trial
+5 more records
Product overview1 text field

Altimmune is a late clinical-stage biopharmaceutical company developing a single lead candidate, pemvidutide, a novel peptide-based therapeutic with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity. The company is advancing this one product across three therapeutic indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company does not offer multiple distinct products or modules—all programs flow from the same core pemvidutide molecule with different therapeutic applications.

Product and service4 records
1Pemvidutide
2Pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
3Pemvidutide for Alcohol Use Disorder (AUD)
4Pemvidutide for Alcohol-Associated Liver Disease (ALD)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Late-stage MASH-focused biopharmaceutical company with the first FDA-approved MASH therapy (Rezdiffra/resmetirom). Most direct comparable to Altimmune given similar therapeutic focus, late-stage clinical positioning, and target patient population in MASH.

TypeDirect peer
Description

Clinical-stage biotechnology company developing efruxifermin (FGF21 analog) for MASH. Directly comparable to Altimmune in therapeutic area, stage of development, and target patient population, with overlapping metabolic mechanism.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing pegozafermin (FGF21 analog) for MASH. Closely comparable to Altimmune given similar therapeutic indication, similar late-Phase-stage profile, and similar company size and focus.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing dual GLP-1/GIP receptor agonist VK2735 for obesity and related metabolic diseases. Directly comparable mechanism family to pemvidutide and similar late-stage clinical positioning.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing lanifibranor (pan-PPAR agonist) for MASH. Direct comparable in therapeutic area, clinical stage, and target indication.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing TERN-501 (THR-β agonist) and other candidates for MASH and obesity. Comparable MASH focus with smaller-stage and earlier clinical position than Altimmune.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing denifanstat (FASN inhibitor) for MASH. Comparable MASH focus and mechanism-based differentiation play, with similar clinical-stage positioning.

8Boehringer Ingelheim / Zealand Pharma
TypeBroad incumbent
Description

Large-cap incumbents developing survodutide (a dual GLP-1/glucagon agonist) for MASH and obesity. Mechanistically closest direct competitor to pemvidutide, but backed by substantially larger commercial and R&D resources.

TypeBroad incumbent
Description

Global pharmaceutical incumbent advancing tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist) into MASH and broader metabolic indications. Represents significant competitive pressure with vastly larger commercial footprint than Altimmune.

TypeBroad incumbent
Description

Global GLP-1 leader advancing semaglutide (Wegovy) into MASH (ESSENCE trial). Dominant incumbent in the GLP-1 class with established hepatology and metabolic disease commercial infrastructure, representing the largest competitive threat to pemvidutide's market opportunity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Altimmune

Clinical-stage Biopharmaceuticalsaltimmune.com

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a proprietary 1:1 glucagon/GLP-1 dual receptor agonist peptide, for the treatment of MASH, AUD, and ALD. The company is pre-commercial and preparing to initiate a Phase 3 trial in MASH.

What Altimmune does

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide-based therapeutic with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity. The company is advancing pemvidutide across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). MASH is the lead indication, where pemvidutide has received both FDA Breakthrough Therapy Designation and Fast Track Designation, supported by positive Phase 2b IMPACT trial data demonstrating 7.5% weight loss, 23.7% triglyceride reduction, 15.4% total cholesterol reduction, and statistically significant MASH resolution without worsening of fibrosis at 24 weeks. AUD has received Fast Track Designation with Phase 2 RECLAIM topline data expected in Q3 2026, and the Phase 2 RESTORE trial in ALD was initiated in July 2025. The technology differentiates from GLP-1-only therapies through direct liver effects mediated by the glucagon receptor pathway.

Altimmune operates as a single-asset company — all three indications flow from the same pemvidutide molecule — and is currently pre-commercial, with Q4 2025 revenue of just $26,000. The company plans to initiate the Phase 3 PERFORMA trial in MASH in H2 2026 with an estimated program cost of approximately $400 million. The business model is pharmaceutical drug development and commercialization; upon approval, revenue is expected to be generated through specialty pharmacy and healthcare provider distribution channels, with analyst peak revenue estimates of $600 million to $1 billion from approximately 20,000 MASH patients.

The company is publicly traded on NASDAQ (ticker: ALT), headquartered in Gaithersburg, MD with a planned relocation to Morristown, NJ in late 2026. As of April 30, 2026, the company held approximately $535 million in cash following two equity offerings in early 2026 totaling approximately $300 million. The senior leadership team was substantially refreshed in 2025-2026 with appointments from Intercept Pharmaceuticals and Sanofi, including CEO Jerome Durso (former CEO/COO of Intercept), CCO Linda Richardson (former CCO of Intercept and Sanofi GLP-1 franchise leader), and CMO Christophe Arbet-Engels (former CMO at X4 Pharmaceuticals, Neurogastrx, and others). The company operates independently without parent or subsidiary structure, though it has secured up to $100 million in debt financing from Hercules Capital in addition to its equity raises.

Altimmune firmographics

Firmographics
Name
Altimmune
Legal name
Altimmune, Inc.
Website
https://altimmune.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a proprietary 1:1 glucagon/GLP-1 dual receptor agonist peptide, for the treatment of MASH, AUD, and ALD. The company is pre-commercial and preparing to initiate a Phase 3 trial in MASH.
Ownership category
akta.pro rank

Altimmune industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Peptide therapeutics development
  • Liver disease treatments
  • MASH drug development
  • Metabolic disease therapeutics
  • GLP-1 glucagon agonists

Where Altimmune is headquartered

Location

Headquarters

HQ city
Gaithersburg
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Altimmune business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide for liver diseases. Once approved, the company plans to commercialize the drug for MASH, AUD, and ALD indications. Analysts estimate peak revenue potential of $600 million to $1 billion from approximately 20,000 patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Altimmune product offering

Product offering

Core offering

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, for the treatment of serious liver diseases. The lead candidate is being advanced across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

Product overview

Altimmune is a late clinical-stage biopharmaceutical company developing a single lead candidate, pemvidutide, a novel peptide-based therapeutic with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity. The company is advancing this one product across three therapeutic indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company does not offer multiple distinct products or modules—all programs flow from the same core pemvidutide molecule with different therapeutic applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pemvidutide
  • Pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Pemvidutide for Alcohol Use Disorder (AUD)
  • Pemvidutide for Alcohol-Associated Liver Disease (ALD)

Quantifiable outcome

  • 7.5% weight loss at 1.8 mg dose vs 0.2% for placebo in 48-week MASH trial
  • +5 more outcomes

Companies that use Altimmune

Customer profile

Segments3 records

Ideal customer profiles2 records

Altimmune technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Altimmune partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Altimmune competitors and assessment

Company assessment

Direct peers

  • Madrigal Pharmaceuticals: Late-stage MASH-focused biopharmaceutical company with the first FDA-approved MASH therapy (Rezdiffra/resmetirom). Most direct comparable to Altimmune given similar therapeutic focus, late-stage clinical positioning, and target patient population in MASH.
  • Akero Therapeutics: Clinical-stage biotechnology company developing efruxifermin (FGF21 analog) for MASH. Directly comparable to Altimmune in therapeutic area, stage of development, and target patient population, with overlapping metabolic mechanism.
  • 89bio: Clinical-stage biopharmaceutical company developing pegozafermin (FGF21 analog) for MASH. Closely comparable to Altimmune given similar therapeutic indication, similar late-Phase-stage profile, and similar company size and focus.
  • Viking Therapeutics: Clinical-stage biopharmaceutical company developing dual GLP-1/GIP receptor agonist VK2735 for obesity and related metabolic diseases. Directly comparable mechanism family to pemvidutide and similar late-stage clinical positioning.
  • Inventiva: Clinical-stage biopharmaceutical company developing lanifibranor (pan-PPAR agonist) for MASH. Direct comparable in therapeutic area, clinical stage, and target indication.

Emerging players

  • Terns Pharmaceuticals: Clinical-stage biopharmaceutical company developing TERN-501 (THR-β agonist) and other candidates for MASH and obesity. Comparable MASH focus with smaller-stage and earlier clinical position than Altimmune.
  • Sagimet Biosciences: Clinical-stage biopharmaceutical company developing denifanstat (FASN inhibitor) for MASH. Comparable MASH focus and mechanism-based differentiation play, with similar clinical-stage positioning.

Broad incumbents

  • Boehringer Ingelheim / Zealand Pharma: Large-cap incumbents developing survodutide (a dual GLP-1/glucagon agonist) for MASH and obesity. Mechanistically closest direct competitor to pemvidutide, but backed by substantially larger commercial and R&D resources.
  • Eli Lilly: Global pharmaceutical incumbent advancing tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist) into MASH and broader metabolic indications. Represents significant competitive pressure with vastly larger commercial footprint than Altimmune.
  • Novo Nordisk: Global GLP-1 leader advancing semaglutide (Wegovy) into MASH (ESSENCE trial). Dominant incumbent in the GLP-1 class with established hepatology and metabolic disease commercial infrastructure, representing the largest competitive threat to pemvidutide's market opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Altimmune social profiles

Digital presence

Altimmune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Altimmune leadership team

Management profile

Number of profiles

Profiles11 records

Altimmune funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Altimmune M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altimmune

What does Altimmune do?

Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide, a novel investigational peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity, for the treatment of serious liver diseases. The lead candidate is being advanced across three indications: metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

Is Altimmune a public or private company?

Altimmune is a public company. It is classified as public and is currently operating.

When was Altimmune founded?

Altimmune was founded in 2005. It employs 51 to 100 people.

Where is Altimmune based?

Altimmune is headquartered in Gaithersburg, United States, in the North America region.

How does Altimmune make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are Altimmune's main competitors?

Direct peers on record are Madrigal Pharmaceuticals, Akero Therapeutics, 89bio, Viking Therapeutics and Inventiva. Emerging players are Terns Pharmaceuticals and Sagimet Biosciences. Broad incumbents are Boehringer Ingelheim / Zealand Pharma, Eli Lilly and Novo Nordisk.

Does Altimmune have an API?

No public API is recorded for Altimmune.

What industry is Altimmune in?

Altimmune's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAltimmune (NASDAQ:ALT) Stock Gets Downgrade from Wall Street ZenWall Street Zen downgraded Altimmune from a sell to a strong sell rating. The stock opened at $1.65, with a consensus rating of Moderate Buy and a target price of $14.33. CEO Jerome Durso bought 30,700 shares, increasing his stake by 49.12%.TradingViewB. Riley Securities maintains Altimmune at Buy, lowers price target to $11 from $13B. Riley Securities maintained Altimmune at Buy and lowered its price target to $11 from $13, a 15.4% decrease. The target implies an upside of 583.2% from the Nov 12 close of $1.61.StocktwitsWhy Did NVDA, ALT, PLUG Stocks Plunge To 52-Week Lows Today?Nvidia, Altimmune, and Plug Power stocks fell to 52-week lows on Thursday amid leadership turmoil, weak earnings, and Wall Street caution. Nvidia's CEO Jensen Huang stepped down, Altimmune posted a wider-than-expected Q3 loss, and Plug Power's Q3 earnings were weak with cash burn concerns.Investing.comEarnings call transcript: Altimmune Q3 2026 loss widens as stock falls 5.4%Altimmune reported a Q3 2026 loss of $31.6 million, missing the $0.13 loss estimate by $0.02, and shares fell 5.44% to $1.825. The company held $480 million in cash, with management saying it should fund operations through the 2029 PERFORMA MASH readout.BenzingaAltimmune Q3 2026 Earnings Call Transcript - Altimmune (NASDAQ:ALT)Altimmune reported a Q3 2026 net loss of $31.6 million, with R&D expenses rising to $27 million due to Phase 3 MASH trial initiation. The company holds $480 million in cash and expects the PERFORMA Phase 3 trial readout in 2029. It plans to pursue non-dilutive funding for future program development.MarketScreenerAltimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Altimmune reported a Q3 net loss of $31.61 million and a nine-month net loss of $77 million, both narrower than the prior year. Basic and diluted loss per share from continuing operations were $0.15 and $0.45, respectively, down from $0.21 and $0.74 a year ago.The future of tradingAltimmune posts higher than expected Q3 lossAltimmune reported a Q3 net loss of $31.61 million and a loss per share of $0.15, both missing analyst estimates. The company ended the quarter with $480 million in cash and higher R&D and G&A expenses. It expects topline data from its RESTORE Phase 2 ALD trial in the second half of 2027.Quiver QuantitativeAltimmune Reports $31.6 Million Third-Quarter Loss as Pemvidutide Trials Advance | ALT Stock NewsAltimmune reported a Q3 2026 net loss of $31.6 million, with no revenue and $480 million in cash. R&D expenses rose to $27.0 million, and its global PERFORMA Phase 3 trial in MASH is progressing as planned. Pemvidutide Phase 2 data are expected in December 2026.The Pharma LetterAltimmune’s pemvidutide shows significant antifibrotic improvements in MASH trialAltimmune published 48-week results from the IMPACT Phase IIb trial of pemvidutide in MASH patients, showing significant reductions in liver fat, inflammation, and fibrosis, plus weight loss. The dual receptor agonist's data was published in The Lancet Gastroenterology & Hepatology, and Altimmune's shares fell 8.3% to $1.77.BioSpaceAltimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorderAltimmune will meet the FDA next month on its Phase 3 program for pemvidutide, a glucagon/GLP-1 dual agonist for alcohol use disorder. The drug reduced heavy-drinking days by 4.2 per week versus 2.75 in a Phase 2 trial, and analysts cite a 38% reduction in serum PEth as strong validation. The company has $519 million in cash and recently started a Phase 3 trial in MASH.